{"id":262843,"date":"2025-02-06T13:02:23","date_gmt":"2025-02-06T12:02:23","guid":{"rendered":"https:\/\/sola-diagnostics.com\/?p=262843"},"modified":"2025-02-06T14:32:22","modified_gmt":"2025-02-06T13:32:22","slug":"wid-easy-test-on-orf-bewusst-gesund","status":"publish","type":"post","link":"https:\/\/sola-diagnostics.com\/en\/wid-easy-test-on-orf-bewusst-gesund\/","title":{"rendered":"WID\u00ae-easy Test on ORF: ‘Bewusst Gesund’"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”WID\u00ae-easy Test on ORF: 'Bewusst Gesund' reports on new possibilities for early cancer detection” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

On February 1, 2025, the WID\u00ae-easy Test<\/strong> was presented in the ORF program “Bewusst Gesund”<\/a><\/strong>. The report shows how this innovative epigenetic test revolutionizes the early detection of uterine cancer and can spare affected women invasive procedures. <\/p>\n

[\/et_pb_text][et_pb_heading title=”Uterine cancer: the most common gynecological cancer” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Uterine cancer is the most common gynecological cancer – even more common than cervical cancer. This not only affects older women, but also younger women. A research team<\/strong> led by Prof. Dr. Martin Widschwendter<\/strong> has made significant progress in detecting carcinomas of the uterus earlier and more reliably. <\/p>\n

[\/et_pb_text][et_pb_heading title=”WID\u00ae-easy Test: Precision diagnosis through epigenetic analyses” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

The ORF report particularly emphasizes the WID\u00ae-easy Test<\/strong>. Using an epigenetic analysis, the test can identify malignant changes at an early stage. This enables timely, targeted treatment and can spare affected women invasive procedures. <\/p>\n

Another test method for the early detection of cervical cancer<\/strong> is currently under development<\/strong>. Initial results show that the test can identify 69% of women who could develop cervical cancer or a preliminary stage within the next one to six years<\/strong> by analyzing a simple smear test. <\/p>\n

[\/et_pb_text][et_pb_heading title=”Medical progress for women's health” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

The WID\u00ae-easy Test represents a significant advance in gynecology, as it not only makes the diagnosis more precise, but also reduces the risk of unnecessary treatment. The test is already available in Austria, Switzerland and the UK and offers a new option for early cancer detection. <\/p>\n

You can find the complete ORF report here: ORF Mediathek<\/a><\/strong><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

On February 1, 2025, the WID\u00ae-easy Test was presented in the ORF program “Bewusst Gesund”. The report shows how this innovative epigenetic test is revolutionizing the early detection of uterine cancer and can spare affected women invasive procedures. <\/p>\n","protected":false},"author":4,"featured_media":262869,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-262843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts\/262843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/comments?post=262843"}],"version-history":[{"count":0,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/posts\/262843\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media\/262869"}],"wp:attachment":[{"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/media?parent=262843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/categories?post=262843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sola-diagnostics.com\/en\/wp-json\/wp\/v2\/tags?post=262843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}